Compare Advance Auto Parts, Inc. (AAP) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advance Auto Parts, Inc. vs Amphastar Pharmaceuticals Inc — how do they compare? Advance Auto Parts, Inc. trades at $52.93 (market cap $3.36B), while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M). The key difference: Advance Auto Parts, Inc. is far larger — about 3.9× Amphastar Pharmaceuticals Inc's market cap, and Advance Auto Parts, Inc. pays a 1.79% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AAP | AMPH | |
|---|---|---|
Market Cap | $3.36B | $863.95M |
Sector | Consumer Cyclical | Health |
52-Week High | $64.17 | $30.81 |
52-Week Low | $38.75 | $16.87 |
Enterprise Value | $5.63B | $1.26B |
Dividend Yield | 1.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $57.80, down 0.21% on the day, with a bullish technical signal and key support at $57. The company shows mixed fundamentals: a low P/S of 0.41 and strong recent earnings beats, but thin net margins of 0.51% and negative operating cash flow in 2025. News highlights restructuring efforts and AI-driven delivery initiatives as potential growth catalysts.
The outlook is cautiously optimistic; analyst consensus targets $61.30 with a buy rating, but high debt and competitive pressures pose risks. Earnings momentum and valuation appeal offer upside, yet execution on turnaround plans is critical for sustained recovery.
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
